We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Healthcare Ent. | LSE:HCEG | London | Ordinary Share | GB00B6030H73 | ORD 25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
24/8/2010 20:20 | Here you go then ....... | substp | |
24/8/2010 18:41 | Substp/Mark30. A GOLDEN OPPORTUNITY. Rememember when that Warrington based airline wanted to use a disinfectant cleaner on their aircraft and Hceg had multi gallons of it on the warehouse shelves at Warrinmgton and unbelievably missed the opportunity. Well Warrington Trust have just become the only trust to refuse IVF treatment due to cost. | willib2 | |
14/8/2010 17:02 | Substp. My goodness, they have a lot to answer for. Lot of bananas that. | willib2 | |
14/8/2010 10:50 | £1,234.00 LOL | substp | |
13/8/2010 22:29 | Substp. How much would the share price have to be for you to break even. | willib2 | |
13/8/2010 08:01 | Intellectual Property (IP) & Regulatory: The Evie device is a registered patent in the US and EU (US Patent 7,331,923 B2). CE approved (2010) for sale in European Union countries FDA approved (2010) for sale in the United States and dependencies Competitive Comparison: The infertility device sector is a competitive market with a number of players that develop, manufacture and distribute devices for IUI and ART among them are: Smith Medical, Cook Medical, Cooper Surgical and Vitrolife. As was confirmed during the FDA approval process, there is no directly comparable product to the EVIE in the US market, nor to our knowledge, in other markets. On average one million ART cycles are performed each year worldwide. This translates into a global Fertiligent market opportunity of about 4 million IUI cycles per year and the annual market opportunity of the Fertiligent EVIE at retail level is around $1 billion. Size ( I would take this part with a pinch of salt :-) ) Manufacture: Fertiligent has contracted with Catheter Research Inc.("CRI") of Indianapolis, USA to assemble the product, using CRI's proprietary balloon catheter as a key component. Other parts are sourced in Israel and China and all assembly is carried out in CRI's certified plant in Indianapolis. Distribution: RSL, which owns the worldwide rights to the product, is commencing negotiations with interested parties in various worldwide locations, for the distribution of the product. | substp | |
13/8/2010 07:36 | This is a long but very good read to the end ! Was updated 2 1/2 months ago ..... | substp | |
12/8/2010 18:29 | LOL Mark good spot ..... Almost brought me to tears once before ..... | substp | |
12/8/2010 18:25 | Nordic Surgical Ltd. Unit 71 Basepoint Bournemouth Enterprise Close You have to laugh :0) £1 by Christmas eh sub's :0) | mark30 | |
12/8/2010 18:13 | "Nordic Surgical specialises in the distribution of surgical and medical products throughout Europe, the Middle East and Africa. In addition, we offer consulting and training services" "July 13th. Nordic Surgical are proud to annouce a new partnership with Ebiox Advanced Decontamination Technology products. Nordic will now be distributing Ebiox products in the UK. " We are attending a number of surgical Congresses in 2010. Please see our diary below to find out where you can come and meet us to see how we can help your practice or hospital. Next Congress Date BOA/World Orthopaedic Congress, Glasgow 13-16 September, 2010 IPS Infection Prevention 2010, Bournemouth 20-22 September, 2010 AAGBI Annual Scientific Meeting, Harrogate 22-24 September, 2010 AFPP, Perioperative Practitioners, Harrogate 14-16 October, 2010 | substp | |
12/8/2010 16:16 | "Nighthawk taking people to court for defamitory remarks on this board," LOL Willie, where have I heard that before :0) I think I'm in good company actually and particularly given our history. Life in the old dog yet mind :0) | mark30 | |
12/8/2010 15:52 | Hello boyo. Glad to see you still in the land of the living and as buoyant as ever. | willib2 | |
12/8/2010 15:44 | And let's not forget RSL with its US FDA approval and being manufactured by Catheter Research Inc . You know ..... the one that is looking for someone to market it ....... RSL 27% owned by HCEG with 200,00 redeemable shares Hello Willib ! | substp | |
12/8/2010 15:42 | Mark30. "But let's not forget,this lot couldn't run a bath", Be careful old boy, Nighthawk taking people to court for defamitory remarks on this board, and we dont want to see your many holdings substantially reduced because of nefarious comments. | willib2 | |
12/8/2010 15:37 | Mark30. Funny really cos I have just arrived back from the hallowed turf, and couldnt believe my eyes when I saw 6 new posts, made a good day even better. Zapa not very friendly though, time obviously doesnt heal. Had only been thinking recently that Subs seemed to have dissapeared, obviously not the case, a champion ferreter. This does create a dilemna for some though, should one buy at this low price and hope for a resurgence or wait and hope to recover against their original substantial losses. I will watch the trades with interest. Ps, from the interims Ebiox Limited The Group's majority shareholding in Ebiox Limited ("Ebiox") was disposed of in July 2009 as part of the restructuring of its liabilities. Consequently Ebiox was accounted for as an associate entity during the period and HCEG's share of associate losses was £36,000. The Group held approximately 21% of Ebiox's ordinary share capital as at 31 December 2009 and £500,000 of redeemable preference shares. | willib2 | |
12/8/2010 15:35 | Hi Zapa , Mark and everyone else . For those that hold ..... All of the best ..... :-) | substp | |
12/8/2010 15:07 | He'll be along zapa make no mistake lol Actually haven't seen him around lately, maybe a new name now. | mark30 | |
12/8/2010 14:53 | Hallo Mark, like old times, just need a nine iron swinging loony now. :) | zapa | |
12/8/2010 14:51 | Yes interesting, took a while mind! But let's not forget,this lot couldn't run a bath, just maybe the UK's NHS might develop some Dutch courage eh! | mark30 | |
12/8/2010 14:00 | I'm curious if there has been any progress ......Is Ebiox in the last one ? "The contents of this website are under review, following the formation of a new HM Government.Current information may be found at www.dh.gov.uk" and 13/05/10 "Conversely, those who make hand hygiene products are convinced there is a solution and at least two companies have developed non-alcohol alternatives for waterless hand decontamination. Andrew Brentnall, spokesman for NHS Supply Chain, has confirmed that the organisation will be conducting a pilot study on these non-alcohol gels to seek assurance that they perform to the same level of efficacy as alcohol gels and are compliant with the relevant standards (EN 1500). He said: "If the pilot is successful we will then launch a full tender programme." Products selected for the Supply Chain catalogue become available to NHS units though the national distribution system, but manufacturers of the non-alcohol products involved in the pilot study have deferred comment pending outcome of the study. "In the meantime," Brentnall said, "NHS units are not restricted from their own investigation and purchase of alternative products."" | substp | |
12/8/2010 11:45 | very interesting ...... | substp | |
02/5/2010 16:08 | Mark30. Never have been (Personally) as you know, but as I have said in the past I always had a very good reason to watch, Mmmmmmm its progress. Clubs never need dusting off, its a 52 week programme, and still looking to emulate your good fortune. (Was it last year). As they say, We may disagree but no need to be disagreeable. Well not on this particular thread. | willib2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions